Regen BioPharma ‘s Chief Scientific Officer Examines Potential Role Of Immunotherapeutic Treatment For Ebola In Conjunction With Other Current Therapies

SAN DIEGO, CA--(Marketwired - October 28, 2014) - Regen BioPharma Inc.'s (OTCBB: RGBP) Chief Scientific Officer Dr. Thomas Ichim stated today that The Company is currently identifying potential immunotherapeutic treatments that might have value in treating some of the effects of Ebola in conjunction with other treatments. The goal of using immunotherapy in mitigating some of the side effects of Ebola is to jump start the body’s own immune system to identify and fight off these potentially fatal conditions.

Thomas Ichim, PhD, said, “We know that one of the side effects of Ebola is the destruction of blood vessels causing internal hemorrhaging. There are certain immunotherapeutic approaches to addressing this potentially fatal condition that can be adapted from research pertinent to this area. Currently, Regen has an interest in developing this approach, whether as a standalone therapy or in use as a combination therapy.”

Regen’s Chairman & CEO David Koos provided further clarifying comments: “While we at Regen are interested in immunotherapeutic treatments for addressing ailments such as aplastic anemia and gene silencing for cancer, we believe that immunotherapeutic approaches to other areas such as Ebola may result in effective therapies as well. We are examining several forms of immunotherapy which we believe may prove beneficial in the battle against this deadly disease. Our research is extremely early stage at this point. At this time, we believe any such therapy may require a long period of development as Ebola is an extremely dangerous disease and requires the utmost care in moving forward with any research.”

About Regen BioPharma Inc.: Regen BioPharma Inc. (OTCBB: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.

Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company’s website http://www.regenbiopharma.com/

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.